Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
VANCOUVER, British Columbia and WARMINSTER, Pa., Aug. 14, 2017 -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the company will present a corporate overview and business update at the 2017 Wedbush PacGrow Healthcare Conference at 10:55am ET on Wednesday, August 16, 2017, at Le Parker Meridien in New York.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit www.arbutusbio.com.
Contact Information Investors Adam Cutler Senior Vice President, Corporate Affairs Phone: 604-419-3200 Email: [email protected] Tiffany Tolmie Manager, Investor Relations Phone: 604-419-3200 Email: [email protected] Media David Schull Russo Partners Phone: 858-717-2310 Email: [email protected]
